<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741013</url>
  </required_header>
  <id_info>
    <org_study_id>05-1137</org_study_id>
    <nct_id>NCT00741013</nct_id>
  </id_info>
  <brief_title>Quantifying Airway Inflammation With Radiologic Tests</brief_title>
  <official_title>Imaging Biomarkers of Pulmonary Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barnes-Jewish Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, double-blind, placebo controlled trial we used positron emission
      tomography to determine if lovastatin or recombinant human activated protein C exhibit
      anti-inflammatory effects in humans following intrabronchial installation of
      lipopolysaccharide (LPS or endotoxin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quantitative, noninvasive biomarkers for lung-specific inflammation have yet to be developed
      but can potentially contribute significantly to the development of therapies to treat lung
      inflammation. The purpose of this study was to demonstrate that positron emission tomographic
      (PET) imaging with [18F}fluorodeoxyglucose (FDG-PET) can be used to quantify the change in
      lung inflammation in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation</measure>
    <time_frame>24 hours after endotoxin instillation</time_frame>
    <description>Calculated Ki was used to measure the amount of lung inflammation before and after instillation of endotoxin to assess the effect of placebo, lovastatin, and rhAPC treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Total Nucleated Cells From Bronchoalveolar Lavage (BAL) Fluid 24 Hours After Endotoxin Instillation</measure>
    <time_frame>24 hours after endotoxin instillation</time_frame>
    <description>Number of total nucleated cells isolated from the first aliquoe of BAL obtained to correlate with PET data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lung Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo pill and placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovastatin pill and placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill and rhAPC IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill and placebo IV</intervention_name>
    <description>Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS</description>
    <arm_group_label>Placebo pill and placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin pill and placebo IV</intervention_name>
    <description>lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS</description>
    <arm_group_label>Lovastatin pill and placebo IV</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill and recombinant human activated protein C IV</intervention_name>
    <description>placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS</description>
    <arm_group_label>Placebo pill and rhAPC IV</arm_group_label>
    <other_name>Xigris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.</description>
    <arm_group_label>Placebo pill and placebo IV</arm_group_label>
    <arm_group_label>Lovastatin pill and placebo IV</arm_group_label>
    <arm_group_label>Placebo pill and rhAPC IV</arm_group_label>
    <other_name>Reference Endotoxin (E. Coli O113:H10K)</other_name>
    <other_name>lipopolysaccharide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, man or woman, any race or ethnicity, age 19 - 44 years old

          -  Screening FEV1 and FVC must be &gt; 80% of predicted.

          -  Screening oxygen saturation by pulse oximetry is &gt;97% on room air.

          -  Research volunteer must be capable of lying still and supine within the PET scanner
             for ~2 Â½ hours.

          -  Research volunteer must be capable of fasting for 6 hours.

        Exclusion Criteria:

          -  Pregnancy (confirmed by a qualitative urine hCG pregnancy test)

          -  Lactation.

          -  Actively menstruating at time of randomization

          -  History of tobacco use or has smoked other illicit drugs (marijuana, cocaine) in the
             past year.

          -  Research volunteer is currently taking any prescription medications.

          -  Research volunteer is at increased risk for radiation exposure (e.g. flight
             attendants)

          -  Research volunteer is enrolled in another research study of an investigational drug.

          -  Research volunteer has a known allergy to both trimethoprim/sulfamethoxazole and
             amoxicillin.

          -  Research volunteer has a known allergy to drugs routinely used during bronchoscopy.

          -  Research volunteer has a known allergy to lovastatin or rhAPC

          -  Fasting glucose at time of PET study &gt; 150 mg/dl.

          -  Exclusion criteria related to use of rhAPC:

               -  Active or history of internal bleeding within the past 3 months

               -  History of hemorrhagic stroke within the past 3 months.

               -  History of intracranial or intraspinal surgery, or severe head trauma, within the
                  past 3 months

               -  History of trauma with an increased risk of life-threatening bleeding within the
                  past 3 months

               -  History of receiving thrombolytic therapy within the past 3 months.

               -  History of receiving oral anticoagulants or glycoprotein IIb/IIIa inhibitors
                  within the past 3 months.

               -  History of using aspirin &gt; 650 mg/d or other platelet inhibitors within the past
                  7 days.

               -  Any history of intracranial arteriovenous malformation or aneurysm

               -  Any history of a known bleeding diathesis

               -  Any history of chronic severe hepatic disease

               -  Presence of an epidural catheter

               -  Any history of intracranial neoplasm or mass lesion or evidence of cerebral
                  herniation

               -  Use of heparin during past 7 days

               -  Platelet count &lt;100,000 x 106/L

               -  Prothrombin time-INR &gt; 1.5

               -  SGOT &gt;47 IU/L, SGPT &gt; 53 IU/L, or bilirubin &gt; 1.1 mg/dl

               -  Any other condition in which bleeding constitutes a significant hazard or would
                  be particularly difficult to manage because of its location.

          -  Exclusion criteria related to use of lovastatin:

               -  History of chronic active liver disease or acute liver disease within the past 3
                  months

               -  SGOT &gt;47 IU/L, SGPT &gt; 53 IU/L, or bilirubin &gt; 1.1 mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine L Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen DL, Bedient TJ, Kozlowski J, Rosenbluth DB, Isakow W, Ferkol TW, Thomas B, Mintun MA, Schuster DP, Walter MJ. [18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. Am J Respir Crit Care Med. 2009 Sep 15;180(6):533-9. doi: 10.1164/rccm.200904-0501OC. Epub 2009 Jul 2.</citation>
    <PMID>19574441</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <results_first_submitted>August 4, 2009</results_first_submitted>
  <results_first_submitted_qc>April 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>lung inflammation</keyword>
  <keyword>lovastatin</keyword>
  <keyword>recombinant human activated protein C</keyword>
  <keyword>endotoxin</keyword>
  <keyword>fluorodeoxyglucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
    <mesh_term>Protein C</mesh_term>
    <mesh_term>Drotrecogin alfa activated</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Pill and Intravenous (i.v.) Placebo</title>
          <description>Control group receiving only placebo drug interventions</description>
        </group>
        <group group_id="P2">
          <title>Lovastatin Pill and i.v. Placebo</title>
          <description>Group receiving lovastatin as the primary drug intervention</description>
        </group>
        <group group_id="P3">
          <title>Placebo Pill and Recombinant Human Activated Protein C i.v.</title>
          <description>Group receiving recombinant human activated protein C (rhAPC) as the drug intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discovered failed screen after enrolled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Pill and Intravenous (i.v.) Placebo</title>
          <description>Control group receiving only placebo drug interventions</description>
        </group>
        <group group_id="B2">
          <title>Lovastatin Pill and i.v. Placebo</title>
          <description>Group receiving lovastatin as the primary drug intervention</description>
        </group>
        <group group_id="B3">
          <title>Placebo Pill and Recombinant Human Activated Protein C i.v.</title>
          <description>Group receiving recombinant human activated protein C (rhAPC) as the drug intervention</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation</title>
        <description>Calculated Ki was used to measure the amount of lung inflammation before and after instillation of endotoxin to assess the effect of placebo, lovastatin, and rhAPC treatment</description>
        <time_frame>24 hours after endotoxin instillation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill and Intravenous (i.v.) Placebo</title>
            <description>Control group receiving only placebo drug interventions</description>
          </group>
          <group group_id="O2">
            <title>Lovastatin Pill and i.v. Placebo</title>
            <description>Group receiving lovastatin as the primary drug intervention</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and Recombinant Human Activated Protein C i.v.</title>
            <description>Group receiving recombinant human activated protein C (rhAPC) as the drug intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation</title>
          <description>Calculated Ki was used to measure the amount of lung inflammation before and after instillation of endotoxin to assess the effect of placebo, lovastatin, and rhAPC treatment</description>
          <units>Change in Ki</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="9.2"/>
                    <measurement group_id="O2" value="8.4" spread="4.3"/>
                    <measurement group_id="O3" value="14.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-way analysis of variance was performed to determine whether lovastatin or rhAPC effectively reduced endotoxin-induced lung inflammation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Only a single statistical analysis was performed upon completion of the study.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Nucleated Cells From Bronchoalveolar Lavage (BAL) Fluid 24 Hours After Endotoxin Instillation</title>
        <description>Number of total nucleated cells isolated from the first aliquoe of BAL obtained to correlate with PET data.</description>
        <time_frame>24 hours after endotoxin instillation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill and Intravenous (i.v.) Placebo</title>
            <description>Control group receiving only placebo drug interventions</description>
          </group>
          <group group_id="O2">
            <title>Lovastatin Pill and i.v. Placebo</title>
            <description>Group receiving lovastatin as the primary drug intervention</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and Recombinant Human Activated Protein C i.v.</title>
            <description>Group receiving recombinant human activated protein C (rhAPC) as the drug intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Nucleated Cells From Bronchoalveolar Lavage (BAL) Fluid 24 Hours After Endotoxin Instillation</title>
          <description>Number of total nucleated cells isolated from the first aliquoe of BAL obtained to correlate with PET data.</description>
          <units>cells per cubic mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545" spread="425"/>
                    <measurement group_id="O2" value="311" spread="237"/>
                    <measurement group_id="O3" value="520" spread="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Pill and Intravenous (i.v.) Placebo</title>
          <description>Control group receiving only placebo drug interventions</description>
        </group>
        <group group_id="E2">
          <title>Lovastatin Pill and i.v. Placebo</title>
          <description>Group receiving lovastatin as the primary drug intervention</description>
        </group>
        <group group_id="E3">
          <title>Placebo Pill and Recombinant Human Activated Protein C i.v.</title>
          <description>Group receiving recombinant human activated protein C (rhAPC) as the drug intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased pulmonary function</sub_title>
                <description>A drop of greater than 20% from baseline in FEV1 was considered a serious adverse event warranting withdrawal from the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Body ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>General body discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Symptom reported within 48 hours of endotoxin administration.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash under neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Delphine L. Chen</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-7029</phone>
      <email>chend@mir.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

